BCL2 and glioblastoma: The Bcl-2 family proteins are heterogeneously expressed in glioblastoma as about 30%[23] to 60%[24] shows over-representation of these proteins.[24-26] Moreover, Bcl-XL levels in patient-derived GSC cultures have shown a relationship with resistance to HDACi/RTx response.[8] Here, we demonstrate that Obatoclax acted synergistically with HDACi and show efficacy in a large set of patient-derived glioblastoma cultures.